3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
434
Carcinoma, Non-Small-Cell Lung
360
Neoplasms
339
Prostatic Neoplasms
276
Colorectal Neoplasms
264
Multiple Myeloma
206
Lung Neoplasms
195
Neoplasm Metastasis
179
Leukemia, Myeloid, Acute
160
Ovarian Neoplasms
155
Pancreatic Neoplasms
152
Squamous Cell Carcinoma of Head and Neck
138
Melanoma
126
Recurrence
104
Head and Neck Neoplasms
99
Glioblastoma
99
Carcinoma, Renal Cell
98
Endometrial Neoplasms
96
Carcinoma, Hepatocellular
93
Lymphoma, Non-Hodgkin
92
Precursor Cell Lymphoblastic Leukemia-Lymphoma
91
Lymphoma
91
Triple Negative Breast Neoplasms
90
Stomach Neoplasms
88
Uterine Cervical Neoplasms
85
Brain Neoplasms
85
Lymphoma, Large B-Cell, Diffuse
80
Urinary Bladder Neoplasms
77
Glioma
74
Leukemia, Lymphocytic, Chronic, B-Cell
73
Interventions
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
HER2-positive Metastatic Breast Cancer
×
30 days
×
Clear all
NCT06595563
2026-05-07
ZEPHIR-02
Jules Bordet Institute
Phase 2
Recruiting
87 enrolled